S100A9具有胰岛素独立的抗糖尿病和抗炎作用
Gloria Ursino1,2, Giulia Lucibello1,2, Pryscila D S Teixeira1,2
1Department of Cell Physiology and Metabolism, University of Geneva, 1211 Geneva, Switzerland.
Science advances
|January 3, 2024
概括
研究人员发现了一种新的途径来管理1型糖尿病 (T1DM),而不会导致低血糖症. 在T1DM动物中,S100结合蛋白A9 (S100A9) 治疗改善了血糖控制,并减少了T1DM动物的炎症.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 代谢疾病 代谢疾病
背景情况:
- 1型糖尿病 (T1DM) 是一种自身免疫性疾病,其特征是胰岛素缺乏,导致高血糖症.
- 目前用于T1DM的胰岛素治疗具有低血糖和并发症的风险.
- 需要新的治疗策略来改善血糖控制并减少T1DM的并发症.
研究的目的:
- 研究一种独立于胰岛素信号传递的途径,以改善T1DM的血糖控制.
- 评估S100结合蛋白A9 (S100A9) 在动物模型中治疗T1DM的疗效.
- 阐明S100A9在T1DM中的治疗作用背后的机制.
主要方法:
- 利用T1DM动物模型来评估S100A9与降低胰岛素剂量的同时治疗的影响.
- 研究了托尔类受体4 (TLR4) 在调解S100A9降糖效应中的作用.
- 在接受S100A9.9治疗的T1DM小鼠中评估系统性炎症标志物.
主要成果:
- 通过降低胰岛素剂量,S100A9使得人们能够遵守血糖目标,从而预防低血糖症.
- S100A9显示,Toll类受体在骨肌肉 (肌底和腹膜) 中的葡萄糖摄取量有4个依赖的增加.
- 单独或与低胰岛素的S100A9治疗在T1DM小鼠中消除了系统性炎症.
结论:
- S100A9-TLR4骨肌轴代表了T1DM的新治疗点.
- 在T1DM的背景下,S100A9表现出强大的抗炎作用.
- 这一途径为改善超越传统胰岛素治疗的T1DM管理提供了有希望的策略.
相关概念视频
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
177
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
177
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K


